Early administration of anti-latency reversing therapy and broadly neutralizing antibodies to limit the establishment of the HIV-1 reservoir during initiation of antiretroviral treatment - a randomized controlled trial (eCLEAR)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 16 Oct 2019

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Romidepsin (Primary) ; 3BNC 117; Antiretrovirals
Indications HIV-1 infections
Focus Pharmacodynamics
Acronyms eCLEAR

Most Recent Events

10 Oct 2019 Planned primary completion date changed from 20 Jan 2020 to 20 Mar 2020.
12 Apr 2019 Planned End Date changed from 14 Nov 2018 to 20 Apr 2021.
12 Apr 2019 Planned primary completion date changed from 20 Jan 2019 to 20 Jan 2020.

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Welcome to AdisInsight